Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Yamamoto, Yuki, Kanai, Osamu, Okamura, Misato, Hashimoto, Masayuki, Nakatani, Koichi, Sawai, Satoru, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200083/
https://www.ncbi.nlm.nih.gov/pubmed/32391404
http://dx.doi.org/10.1093/ofid/ofaa126
Descripción
Sumario:Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.

Ejemplares similares